D R LLOYD and J MA RPLES From the Department ofChemical Pathology, Royal Albert Edward Infirmary, Wigtm WNI2NN. UK SUMMARY. Fructosamine was measured in the serum of 62 patients with insulin-dependent diabetes (100) and 32 non-diabetics and the results compared with glycated albumin levels (GSA) measured using the affinity medium Cibarcron blue F3GA.
Good correlations were found both for the 100 patients (r=O'93) and the combined group of 100 plus non-diabetics (r=O·95). We conclude, that fructosamine measurements accurately reflect GSA concentrations, and, therefore. provide a practical method for assessing intermediate term glycaemia in 100.
The achievement and maintenance of euglycaemia is now seen as the ultimate goal in the treatment of insulin-dependent diabetes. To monitor control both long-term (glycated haemoglobin) and intermediate-term (glycated serum proteins) indices have been advocated. The use of glycated haemoglobin (GHb) is, however, limited by its lack of sensitivity for detecting changes, during the preceding 2 weeks.'
Of the intermediate-term indices, measurement of GSA, whose half-life is known precisely, would seem preferable to measurement of total glycated proteins. Unfortunately, methods currently available for GSA estimation are not suited to automation and require considerable technical skill to produce precise results. Ease of automation, low cost and good precision make the fructosamine assay potentially very attractive as a measure of serum glycated protein and a number of reports have found good correlations between fructosamine and GSA in mixed populations of patients with insulin-dependent diabetes (IDD), non-insulindependent diabetes (NIDD) and non-diabetics. [2] [3] [4] In contrast, one recent study involving only patients with 100 in whom glycaemic control might be expected to vary more than NIDO found only a poor relationship between serum fructosamine and GSA. 5 In these studies GSA was measured using aminophenylboronate affinity chromatography. However, a number Correspondence: Dr 0 R Lloyd.
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of problems with this material have been noted. particularly, with regard to variation in the batches of aminophenylboronatc."
To further investigate the relationship we have compared serum fructosamine activity with GSA, determined with the use of Cibacron blue F3GA affinity medium. in a group of patients with IDD.
Patients and methods
Blood was collected from 62 100 out-patients (26 male, 36 female) aged 17-67 years and from 32 out-patients (15 male, 17 female) aged 21-68 years who had no history of diabetes and a random blood glucose of less than 6·0 mmol/L. Serum was stored at -2()"C prior to analysis for fructosamine or GSA. Whole blood. preserved with EDTA, was stored at 4"C for a maximum of 7 days until assay for GHb.
Serum fructosaminc was analysed as reported previously.! but modified as follows for the Greiner C-400 analyser (Greiner Instruments AG, Langenthol, Switzerland): sample volume 30 I.l.L, reagent volume 500 I.l.L, incubation time 12·8 min, reaction pH J()·35, change in absorbance measured at 546 nm using kinetic mode 80. Suitably diluted bovine quality control sera (Seronorm: Nycomed Ltd, Birmingham, UK) standardised against deoxy-l-morpholino-nfructose (Sigma Chemical Co, Poole, UK) was used for calibration. Between-batch and withinbatch imprecision (Cv) using this procedure varies between 2-3% and 1.8-2.3°1.., respectively. the best separation of albumin from other serum proteins. Examination of the 2 mol/L potassium chloride fractions using agarose gel electrophoresis, staining with Amido black and densitometry gave typical albumin contents of between 95-99%. Non-protein serum constituents known to interfere in the nitro-blue tetrazolium reaction (e.g. urate, creatinine, ascorbate) were undetectable in the albumin fractions. Between-batch imprecision (CV) at a normal GSA level (0·023 mmollg) was 7·2%. GSA concentrations in the non-diabetic patients were normally distributed and gave a reference interval (mean±l·96 SO) of 0·0172-0·0282 mmollg. In this same population the reference interval for serum fructosamine was found to be 1,72-2·77 mmollL. Amongst the patients with lOO, serum fructosamine activity correlated well with GSA (r=0·93, P<O·OOl; fructosamine =0·6 GSA +1·1) ( Fig.) . As expected a stronger correlation was found using the data from the combined populations of lOO patients and non-diabetics (r=0·95, P<O·OOl).
No significant difference (P>O·05) was found between the r values given by correlating GHb with fructosamine (r=O·72, P<O·OOl) and GHb with GSA (r=O·66, P<O·OOl). GHb was measured by electroendosmosis followed by densitometry using the Corning glycosylated haemoglobin kit (Corning Medical. Palo Alto. CA. USA). The between-batch imprecision in our laboratory is~(Yo.
GSA was determined after separation of total albumin from serum with Cibacron blue followed by measurement of its ketoamine activity. Cibarcron blue (affi-gel blue. 50-tOO mesh: Bio-Rad Laboratories Ltd. Walford. UK) in Tris-HCI (0,02 mol/L, pH 7·5 at 20°C) I: t (v/v) (3 mL) was aIiquoted into microcolumns with bed support discs above and below the gel (Pierce and Warriner Ltd. Chester. UK) and equilibrated with the same buffer. Sample (250 ul.) was applied to the column, allowed to drain and then washed in with Tris-HCI buffer (500 ilL). The columns were washed by adding 0·5 mollL potassium chloride in Tris-HCI buffer (6 mL) and the eluate discarded. The bound albumin fraction was then collected after elution with 2 mollL potassium chloride in Tris-HCI buffer (6 mL). Albumin was precipitated by the addition of cold 40% (w/v) trichloroacetic acid (500 Ill; final concentration 3%) and the precipitate collected by centrifugation at I ()()() g for 10 min. After decanting the supernatent from the albumin pellet, the tube was left inverted for 2 min and the rim blotted. Cold fructosamine assay buffer (3 mL) was added and the pellet and the walls of the tube carefully washed by slow rotation. The buffer was decanted from the pellet as above and the pellet then redissolved in the assay buffer (250 IJ.L) by initial vigorous mixing followed by rotation at room temperature for 10 min. Ketoamine activity of the albumin fractions were measured on the Greiner G-4()() as for the fructosamine assay but using an increased sample volume of 90 IJ.L. The albumin content of each fraction was also measured on the G-4()() using a serum bromocresol green method, but with a threefold increase in the sample volumes. The analysis for fructosamine activity and albumin content were carried out in duplicate on each fraction. Results were expressed as fructosamine activity per g albumin.
Regression analysis was used to compare variables using Bartletts procedure for bivariate data sets. Correlation coefficients were compared by a two-sided Student's r-test following z transformation.
Results
The elution conditions were optimised to give
Discussion
This study demonstrates that measurement of serum fructosamine does reflect levels of GSA in IDD patients. Of the 62 patients studied only three gave results that might be considered discrepant i.e. two patients had normal fructosarnine, but abnormal GSA values and one had a normal GSA, but abnormal fructosamine result. However, these measurements were all close to the limits of their, respective, reference intervals and may represent statistical variance rather than biochemical variation. A previous study that used an approach to the measurement of GSA similar to that used in this study also reported a good correlation between fructosamine and GSA (r=0·92), but the composition of the diabetic population studied was not given." As fructosamine is a measure of all glycated serum proteins the theoretical argument that its measurement will not accurately reflect levels of GSA does not seem to be born out in practice. As Lemon and Forrest" have shown, the in vivo differences in half-life of the various serum proteins appear to have little influence on the fructosamine activity of the protein. We conclude that, measurement of serum fructosamine does accurately reflect levels of GSA and, therefore, represents a practical and precise method of assessing intermediate control in IDD patients.
